SkinBioTherapeutics Plc
SBTX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | – | £41,257 | £17,575 | £26,976 |
| - Cash | £4,779 | £1,237 | £801 | £2,841 |
| + Debt | £881 | £1,026 | £819 | £97 |
| Enterprise Value | – | £41,047 | £17,593 | £24,232 |
| Revenue | £3,062 | £1,577 | £1,102 | £107 |
| % Growth | 94.1% | 43.1% | 934% | – |
| Gross Profit | £1,828 | £878 | £574 | £68 |
| % Margin | 59.7% | 55.6% | 52.1% | 64% |
| EBITDA | £658 | -£881 | -£1,396 | -£1,362 |
| % Margin | 21.5% | -55.9% | -126.7% | -1,278% |
| Net Income | £338 | -£1,034 | -£1,541 | -£1,335 |
| % Margin | 11% | -65.6% | -139.8% | -1,252.6% |
| EPS Diluted | 0.001 | -0.005 | -0.008 | -0.008 |
| % Growth | 128.3% | 41.8% | -5.3% | – |
| Operating Cash Flow | -£495 | -£803 | -£1,398 | -£1,365 |
| Capital Expenditures | -£4 | -£3 | -£13 | -£15 |
| Free Cash Flow | -£499 | -£806 | -£1,411 | -£1,380 |